Marcelo Costa

Board Certified Hepatologist / Gastroenterologist | Medical Affairs | R&D | HepGastro Consulting LLC

[Calvin Koh, MBBS FRCP, FASGE @DrCalvinKoh]

In an Asian multinational non-obese NAFLD cohort, FIB4 has the best performance for significant fibrosis. Do you use it in your practice? #livertwitter #nafld #GITwitter #GOASIA @ajay_duseja @VWSWong @WahKheong @jonathanlwj @dreunicetan @drkeithsiau https://t.co/3Dfgmopm2k

[Marcelo Costa @hepgastro]

@BavenoVII @jaumebosch9 @ggarciatsao Magic trio! RG will be missed dearly.

[WebMD @WebMD]

New research suggests that drinking coffee may reduce your risk for liver disease -- as long as you have three to four cups a day. https://t.co/SwZYlQMxoU

[Marcelo Costa @hepgastro]

@DrLoomba @NAFLDresearch Great program today! @DrLoomba @AASLDtweets

[Marcelo Costa @hepgastro]

Let's go!@AASLDtweets #ETC_nash

[Marcelo Costa @hepgastro]

@NoureddinMD @AlkhouriNaim @NoureddinNabil @DrLoomba @DrMTLong @JasmohanBajaj @AtoosaRabiee @NASH_and_coffee @AASLDtweets @NoureddinMD great tweet! >4/d is my routine

[Liver Canada @LiverCanada]

Your liver cleanses your blood, regulates your body’s energy supply, creates many of your essential proteins, regulates your hormone balance, cholesterol and supply of vitamins and minerals, and produces bile to help your body digest and eliminate toxins. #LiverHealth

[Nature Reviews Gastroenterology & Hepatology @NatRevGastroHep]

@Drfattyliver @NoureddinMD Here's the read-only link: https://t.co/SrOhJNupaJ

[Maria Reig @ma5RN]

Sometimes it happens ...GUT and JHEP acceptance- same day. International-multidisciplinar study focus on #DAA #HCC recurrence. Different views, join efforts: the best work that we could do. Thanks all for your commitment. New project is cooking @BCLC_group @cabibbo78 @docamitgs

[Marcelo Costa @hepgastro]

Dynamic Shifts in the Composition of Resident and Recruited Macrophages Influence Tissue Remodeling in NASH https://t.co/JfxQDQ33p1

[Joe Biden @JoeBiden]

Let me be very clear: the scenes of chaos at the Capitol do not represent who we are. What we are seeing is a small number of extremists dedicated to lawlessness. This is not dissent, it's disorder. It borders on sedition, and it must end. Now.

[Journal of Hepatology @JHepatology]

Are you interested in hepatobiliary transport activities, biliary acid-base homeostasis, bile transport & #cholestasis?

Read this comprehensive review by Ulrich Beuers, David Trampert & colleagues.

🔓 Open access at https://t.co/wzIOfZuSna
#PCB #livertwitter

[Journal of Hepatology @JHepatology]

The pathogenic mechanisms linking #NAFLD/NASH to #HCC are poorly understood. This review discusses current knowledge of how hepatokines and adipokines affect the pathogenesis of #NASH-related HCC and potential clinical applications.

Read 🔓 open access at https://t.co/tMisRhohN2

[Marcelo Costa @hepgastro]

I'm attending REUTERS NEXT - uniting global leaders and forward thinkers to reimagine solutions to the challenges the new year brings. Registration is free for a limited time only, register now https://t.co/db5mlTrdCN

[Echosens @Echosens]

We are thrilled to share our brand new video with our new logos, new colors, new style but always the same reason for being: because liver health matters. 2020 has been an unexpected year, but let's not forget that CLD remains a global health issue. #liverhealthmatters #FibroScan

[Marcelo Costa @hepgastro]

@JHepatology @EASLnews #PBC

[Journal of Hepatology @JHepatology]

New Article "Non-invasive stratification of #HCC risk in in #NAFLD using polygenic risk scores".

Read 🔓 open access at https://t.co/lX8dXE4cXP

@lucavalenti75 @uniofgothenburg

[Marcelo Costa @hepgastro]

#MRE taps the whole liver offering a complete perspective on #steatosis and #fibrosis in a quick scan - designed to diagnose, assess treatment response and document dynamic changes in liver stiffness - particularly interesting for #NASH/#MASH patients with progressive phenotype.

[Resoundant @Resoundant]

New study: Magnetic Resonance-Based Assessments Better Capture Pathophysiologic Profiles and Progression in Nonalcoholic Fatty Liver Disease

https://t.co/h5O4mSriwA

[Echosens @Echosens]

Bring liver disease management to a next level with FibroScan® 630 Expert.
✅ Spleen stiffness measurement ✅ Enhanced ergonomics ✅ #FDA Approved
👉 Contact us to discover it: https://t.co/lIvImvsSoi
#FibroScan #LiverHealthMatters

[Journal of Hepatology @JHepatology]

On #WorldDiabetesDay, #EASL & @JHepatology would like to share this top research article which provides evidence of the high prevalence of #NAFLD and #NASH in patients with T2DM. Read here: https://t.co/0FxGa39Gin